364 related articles for article (PubMed ID: 25751759)
21. Long-term survivors of testicular cancer.
Tamboli CP
J Clin Oncol; 2003 Oct; 21(20):3888; author reply 3888-9. PubMed ID: 14551316
[No Abstract] [Full Text] [Related]
22. Infertility with Testicular Cancer.
Ostrowski KA; Walsh TJ
Urol Clin North Am; 2015 Aug; 42(3):409-20. PubMed ID: 26216827
[TBL] [Abstract][Full Text] [Related]
23. Long-term Morbidity of Testicular Cancer Treatment.
Fung C; Fossa SD; Williams A; Travis LB
Urol Clin North Am; 2015 Aug; 42(3):393-408. PubMed ID: 26216826
[TBL] [Abstract][Full Text] [Related]
24. Effect of testicular germ cell tumor therapy on renal function.
Cost NG; Adibi M; Lubahn JD; Romman A; Raj GV; Sagalowsky AI; Margulis V
Urology; 2012 Sep; 80(3):641-8. PubMed ID: 22840865
[TBL] [Abstract][Full Text] [Related]
25. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
26. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer.
Bandak M; Lauritsen J; Johansen C; Kreiberg M; Skøtt JW; Agerbaek M; Holm NV; Daugaard G
Eur Urol Focus; 2020 Jul; 6(4):711-719. PubMed ID: 30482585
[TBL] [Abstract][Full Text] [Related]
27. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
28. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
[TBL] [Abstract][Full Text] [Related]
29. Testicular cancer--discoveries and updates.
Hanna NH; Einhorn LH
N Engl J Med; 2014 Nov; 371(21):2005-16. PubMed ID: 25409373
[No Abstract] [Full Text] [Related]
30. Chronic pain has a negative impact on sexuality in testis cancer survivors.
Pühse G; Wachsmuth JU; Kemper S; Husstedt IW; Evers S; Kliesch S
J Androl; 2012; 33(5):886-93. PubMed ID: 21474790
[TBL] [Abstract][Full Text] [Related]
31. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
32. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
33. [Testicular Cancer: Diagnostics, Therapy and Follow Up].
Kälin M; Mauti L; Pless M
Praxis (Bern 1994); 2016 May; 105(11):643-8. PubMed ID: 27223417
[TBL] [Abstract][Full Text] [Related]
34. Short- and long-term morbidity after treatment for testicular cancer.
Fosså SD; Oldenburg J; Dahl AA
BJU Int; 2009 Nov; 104(9 Pt B):1418-22. PubMed ID: 19840023
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
[TBL] [Abstract][Full Text] [Related]
36. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
37. [Post treatment follow-up of patients with testicular cancer by primary care physicians].
Steiner R; Beyer J
Praxis (Bern 1994); 2014 Jan; 103(3):125-32; quiz 131. PubMed ID: 24468451
[No Abstract] [Full Text] [Related]
38. Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy.
Christensen JF; Tolver A; Andersen JL; Rørth M; Daugaard G; Hojman P
J Clin Endocrinol Metab; 2014 Aug; 99(8):2967-76. PubMed ID: 25050898
[TBL] [Abstract][Full Text] [Related]
39. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
40. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
